Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

Back

ESC2025 Premium Access

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

Session: Pharmacotherapy to improve outcomes in coronary disease

Topic: Clinical

Speaker: Professor R. Rosenson (New York, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Robert Rosenson

Icahn School of Medicine at Mount Sinai, New York (United States of America)

2 presentations

0 follower

7 more presentations in this session

Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial

Speaker: Doctor N. Kruger (Boston, US)

Access

Abstract

Slides

AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies

Speaker: Doctor J. Rosenmeier (Gothenburg, SE)

Side effects of low-dose colchicine in chronic coronary syndromes, the LoDoCo2 trial

Speaker: Miss J. Jannink (Utrecht, NL)

Colchicine in patients with recent myocardial infarction: a systematic review and meta-analysis of randomized controlled trials

Speaker: Ms A. Moiz (Montreal, CA)

PCSK-9 inhibitors vs. ezetimibe for secondary prevention: utilization disparities and clinical outcomes

Speaker: Doctor M. Sghayyer (Birmingham, US)

Access the full session

Pharmacotherapy to improve outcomes in coronary disease

Speakers: Professor R. Rosenson, Doctor N. Kruger, Doctor J. Rosenmeier, Miss J. Jannink, Ms A. Moiz...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources